ABIVAX Société Anonyme

OTCPK:AAVX.F Stock Report

Market Cap: US$636.7m

ABIVAX Société Anonyme Past Earnings Performance

Past criteria checks 0/6

ABIVAX Société Anonyme's earnings have been declining at an average annual rate of -40.6%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 62.5% per year.

Key information

-40.6%

Earnings growth rate

-7.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate62.5%
Return on equity-140.3%
Net Margin-1,964.6%
Next Earnings Update07 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ABIVAX Société Anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:AAVX.F Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 249-17744135
31 Mar 247-16336119
31 Dec 234-14829103
30 Sep 234-1202184
30 Jun 234-921266
31 Mar 234-761057
31 Dec 224-61748
30 Sep 228-54656
30 Jun 222-47463
31 Mar 221-45555
31 Dec 214-42648
30 Sep 210-41624
30 Jun 210-3960
31 Mar 210-3860
31 Dec 200-3860
30 Sep 200-3550
30 Jun 200-3250
31 Mar 200-3150
31 Dec 190-3150
30 Sep 190-2750
30 Jun 190-2350
31 Mar 191-1950
31 Dec 181-1640
30 Sep 181-1440
30 Jun 181-1340
31 Mar 181-1240
31 Dec 170-1140
30 Sep 170-1140
30 Jun 170-1240
31 Mar 170-1340
31 Dec 160-1440
30 Sep 160-1640
30 Jun 160-1740
31 Mar 160-1740
31 Dec 150-1630
30 Sep 150-1430
30 Jun 150-1230
31 Mar 150-820
31 Dec 140-520

Quality Earnings: AAVX.F is currently unprofitable.

Growing Profit Margin: AAVX.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AAVX.F is unprofitable, and losses have increased over the past 5 years at a rate of 40.6% per year.

Accelerating Growth: Unable to compare AAVX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AAVX.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15%).


Return on Equity

High ROE: AAVX.F has a negative Return on Equity (-140.29%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies